It’s been a difficult few years for gene and cell therapy startup Abeona Therapeutics. Its newly crowned chief Carsten Thiel was last year following accusations of unspecified “personal misconduct,” and this September, the FDA on its therapy for a form of “butterfly” disease. But things are beginning to perk up. On Monday, the company said the regulator had lifted its hold and the experimental therapy is now set to be evaluated in a late-stage study. The therapy, EB-101, is being developed to treat recessive dystrophic epidermolysis bullosa, which is caused by the deficiency of the protein COL7 and for which there is no approved therapy. Abeona’s autologous therapy involves transferring COL7A1 genes into a patient’s own skin cells, followin.